INCRETIN PHARMACOLOGY
Semaglutide vs Tirzepatide — Side-by-Side
One receptor or two? A structured comparison of the GLP-1-only and dual GIP/GLP-1 approaches, drawn directly from head-to-head trial data.
The short version
Both compounds on this desk work through the incretin axis — the gut-to-pancreas-to-brain hormone pathway that governs insulin secretion and hunger. Semaglutide activates one receptor in that pathway (GLP-1R); tirzepatide activates two (GIP-R and GLP-1R). In the head-to-head SURMOUNT-5 trial — the first randomised comparison between the two at maximum tolerated doses — tirzepatide produced -20.2% mean weight loss versus -13.7% for semaglutide over 72 weeks, a statistically significant difference (P<0.001) [1]. In glycaemic control, tirzepatide was likewise superior to semaglutide 1 mg across three doses in the SURPASS-2 trial [11].
Both share a similar GI side-effect profile, the same thyroid C-cell boxed warning, and a gallbladder signal tied to rapid weight loss. The main structural difference is one receptor versus two; the main practical difference, in trial data, is the magnitude of weight reduction achieved.
Head-to-head comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist (incretin mimetic) | Dual GIP + GLP-1 receptor agonist (dual incretin mimetic) |
| Receptor targets | GLP-1R | GIPR + GLP-1R |
| Structure | 31-amino-acid acylated GLP-1 analogue | 39-amino-acid GIP-based peptide with C20 fatty diacid arm |
| Half-life | ~7 days | ~5 days |
| Dosing | Once weekly (injection) or once daily (oral) | Once weekly (injection) |
| Primary studied use | T2D, obesity, cardiovascular risk reduction, CKD, MASH | T2D, obesity, sleep apnea |
| FDA approval status | FDA-approved (T2D, obesity, CV risk reduction, CKD [MASH 2025]) | FDA-approved (T2D 2022; obesity 2023; sleep apnea) |
| WADA status | Not specifically prohibited (verify current list) | Not specifically prohibited (verify current list) |
| Head-to-head weight loss (SURMOUNT-5, 72 wk) [1] | -13.7% | -20.2% (P<0.001 vs semaglutide) |
| SURPASS-2 weight difference vs semaglutide 1 mg [11] | Reference | -1.9 kg (5 mg), -3.6 kg (10 mg), -5.5 kg (15 mg) |
| Gastrointestinal AEs | Predominantly mild-moderate; nausea in ~1/3 of patients [5] | Predominantly mild-moderate; GI risk ~2.9x placebo in meta-analyses [9] |
| Gallbladder / biliary disease | Increased (cholelithiasis) [5] | Significantly increased composite RR 1.97 [9] |
| Thyroid C-cell warning | Yes — rodent-derived boxed warning [5] | Yes — rodent-derived boxed warning [8] |
| Lean-mass concern | Yes — meaningful lean-mass fraction in STEP body-composition substudies | Yes — ~25% lean mass in SURMOUNT-1 DXA substudy |
| Weight regain on discontinuation | Substantial (~11.6 pp mean regain in 1 year in STEP extension) | Substantial — SURMOUNT-4 shows regain after stopping |
| Pregnancy | Contraindicated (~5-week clearance after last dose) | Use under medical guidance; label advises caution |
Citation key: [1] SURMOUNT-5 (Aronne 2025); [5] Smits & Van Raalte safety review (2021); [8] Farzam & Patel StatPearls (2024); [9] Zeng et al. meta-analysis (2023); [11] Frias et al. SURPASS-2 (2021).
See the references page for full citations.
How to read this table
The comparison above draws directly from published randomised trials and peer-reviewed reviews — no manufacturer claims, no promotional framing. A few interpretive notes:
On the head-to-head weight numbers: SURMOUNT-5 was conducted at maximum tolerated dose for each participant, not a fixed dose; this design reflects clinical practice but means the weight-loss difference is somewhat dose-dependent. Semaglutide at a lower dose against tirzepatide at a higher dose is not an apples-to-apples potency comparison [1].
On the GI profiles: both drugs produce qualitatively similar GI side effects (nausea, constipation, diarrhea, slowed gastric emptying) for the same mechanistic reason — GLP-1R activation slows the gut. Tirzepatide's somewhat higher discontinuation rate in meta-analyses versus the comparator dulaglutide likely reflects its greater potency rather than a distinct toxicity.
On the gallbladder signal: both compounds show a biliary disease signal. The mechanism — rapid weight loss precipitating gallstones — is not specific to either drug and is a class-level finding for potent weight-loss agents.
On approvals: both are FDA-approved prescription medicines. This desk does not describe sources, costs, or access pathways; it reports what the clinical literature says about each compound's studied indications and safety profile.